Skip to main content

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Hemopexin: un nuevo factor patogénico en las complicaciones microvasculares de la diabetes.

IP: Cristina Hernández Pascual
Collaborators: Marina Lopez Martinez, Ana Boixadera Espax, Alejandra Planas Vilaseca, Patricia Bogdanov Baruj, Pilar Costa Forner
Funding agency: Instituto de Salud Carlos III
Funding: 139150
Reference: PI22/01670
Duration: 01/01/2023 - 31/12/2025

Proyecto PDC2022-133991-I00 financiado por MICIU/AEI/10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR

IP: Rafael Simó Canonge
Collaborators: Anna Duarri Piqué, Cristina Hernández Pascual, Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 128570
Reference: PDC2022-133991-I00
Duration: 01/12/2022 - 30/11/2024

Ministerio de Ciencia

Bloqueo intraocular de la hemopexina: una nueva estrategia para tratar el edema macular diabético

IP: Rafael Simó Canonge
Collaborators: Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 78100
Reference: DTS19/00171
Duration: 01/01/2020 - 31/12/2021

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Josep Sanjose Puig

Josep Sanjose Puig

Tècnic/a Superior Recerca
Clinical Research Development Directorate
Read more
Jordi Gómez i Prat

Jordi Gómez i Prat

Infectious Diseases
Read more
Marta Rebull Santamaria

Marta Rebull Santamaria

Research technician
Biomedical Research in Gynaecology
Read more
Marc Aguilar García

Marc Aguilar García

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.